OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients

Inclusion Criteria

• •1. Laboratory confirmed SARS-CoV-2 infection by real time RT-PCR or positive antigenic test (commercialized assay)
• •2. Asymptomatic or mild to moderate COVID-19 (WHO progression scale \<5. Patients receiving oxygen therapy for reasons other than a pulmonary COVID-19 are eligible).
• •3. ≥ 16 years of age;
• •4. Immunocompromised as defined by ≥ 1 risk factors for severe COVID-19 as assessed by the Federal Office of Public Health (FOPH) list (criteria 5: diseases/treatments leading to immune suppression) or other immunosuppression criteria such as:
• •* Severe immunosuppression (e.g., human immunodeficiency virus (HIV) infection with CD4 + T cell count \<350 / μl)
• •* Neutropenia (\<1000 neutrophils / μl) ≥1 week
• •* Lymphocytopenia (\<200 lymphocytes/μl)
• •* On dialysis treatment
• •* Hereditary immunodeficiencies
• •* Intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time \[an equivalent dose of prednisone \>20 mg/day \> 3 months\], monoclonal antibodies, cytostatics, biological products, everolimus, mTOR inhibitors etc.) in the last 12 months
• •* Active cancer under cytostatics or targeted therapy known to be immunosuppressive (e.g., platinum salts, cyclophosphamide, anthracyclines, taxanes, 5-fluorouracil, gemcitabine, purine inhibitors, proteasome inhibitors) or associated with hematologic toxicity (neutropenia, lymphopenia), for example sunitinib, imatinib, regorafenib.
• •* Aggressive lymphomas (all types)
• •* Acute lymphatic leukemia
• •* Acute myeloid leukemia
• •* Acute promyelocytic leukemia
• •* T prolymphocytic leukemia
• •* Primary central nervous system lymphoma
• •* Stem cell transplantation
• •* Light chain amyloidosis
• •* Chronic lymphoid leukemia
• •* Multiple myeloma
• •* Sickle cell disease
• •* Bone marrow transplant
• •* Organ transplant
• •* Being on the waiting list for an organ transplant
• •5. Willing and able to comply with study requirements and restrictions as described in the informed consent form (ICF)
• •6. Enrolled in or a beneficiary of a Social Security program (State Medical Aid (AME) is not a Social Security program) or holders of health insurance.
• •7. Participant's or its legal representative's signature of the informed consent form